Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=35 Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over…
Phase 2 N=46 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 3 N=527 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Aspergillosis · Invasive Fungal Infection
Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants
Phase 3 N=459 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
N/A N=249 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 3 N=585 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
Fungal Infections · Invasive Pulmonary Aspergillosis
Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001
N/A N=116 An Observational Study of Fungal Biomarkers (MK-0000-089)
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Phase 4 N=88 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Phase 2 N=102 An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
Pulmonary Aspergillosis
Primary: Proportion of Participants Who Completed 12 Weeks of Therapy — 47; 23 Participants
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Phase 4 N=70 Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Invasive Fungal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 55; 9 Participants
Phase 3 N=116 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Aspergillosis
Primary: Number of Participants With an Adverse Event — 15; 6; 57; 27 Participants
Phase 3 N=121 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
Fungal Infection
Primary: Number of Participants With a Significant Drug-related Adverse Experience — 3; 6 Participants
Phase 2 N=112 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Phase 3 N=355 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
Invasive Fungal Disease
Primary: Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) — 7.9; 11.7 percentage of…
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 2 N=20 A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
Candidiasis, Esophageal · Candidiasis, Invasive · Aspergillosis
Primary: Percentage of Participants With an Overall Favorable Response to Therapy — 66.7; 62.5 Percentage of Participants
Phase 2 N=31 A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
Invasive Mucormycosis · Invasive Aspergillosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 29 Participants
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Phase 2 N=20 Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
Aplastic Anemia · Myelodysplastic Syndromes · Fungal Infection
Primary: the Incidence of Proven/Probable/Possible Fungal Infection — 20 Participants
Phase 3 N=450 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Candidiasis, Invasive · Candidemia · Mycoses
Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
N/A N=323 Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…